$Regeneron Pharmaceuticals (REGN.US)$ The judge rejected Reg...
$Regeneron Pharmaceuticals (REGN.US)$ The judge rejected Regeneron's injunction request against Sandoz, which plans to launch its own version of a drug for treating eye diseases such as macular degeneration. This ruling has raised investor concerns about future competition for EYLEA, the company’s primary revenue source. The negative development overshadowed recent positive news regarding Dupixent, another drug that received favorable evaluations for new indications in Europe. The setback for EYLEA has intensified existing worries, as the company’s revenue growth over the past two years has slowed and operating margins have also declined.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Market Insights
Hot Topics
Trump's 'Taco deal' sparks market rebound : Market rebound sustainable ?
1. If tariffs pause, which sectors benefit first? 2. Trump's "threat-compromise" cycle normalizes—how to hedge across assets?
Moo Options Explorer
Apr 7 17:28
Weekly roundup: Tariff turmoil and recession fears dominate
105433263 : This is news from September. Today’s market behavior reflects a classic 'sell the news' scenario as only positive news has been released. Subsequently, it was reported that Catalent is no longer part of the approval documentation, and this manufacturer produces two of its drugs, prompting the market to reprice. The market fears that if this manufacturer does not address issues at its facilities, it could prevent REGN’s two drugs from coming to market.